Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
ASCO 2024 movers – Affimed wins, Caribou loses
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
ASCO 2024 – new matching strategy delays Caribou
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Sana regains some of its shine
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
